Arthritis - Pipeline Review, H2 2014

Date: July 31, 2014
Pages: 154
Price:
US$ 2,000.00 US$ 1,500.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AB9F0A9F266EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Arthritis - Pipeline Review, H2 2014’, provides an overview of the Arthritis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Arthritis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Arthritis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Arthritis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Arthritis Overview
Therapeutics Development
Pipeline Products for Arthritis - Overview
Pipeline Products for Arthritis - Comparative Analysis
Arthritis - Therapeutics under Development by Companies
Arthritis - Therapeutics under Investigation by Universities/Institutes
Arthritis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Arthritis - Products under Development by Companies
Arthritis - Products under Investigation by Universities/Institutes
Arthritis - Companies Involved in Therapeutics Development
Eli Lilly and Company
GlaxoSmithKline plc
Nemucore Medical Innovations, Inc.
Taisho Pharmaceutical Co., Ltd.
Sylentis S.A.
Astellas Pharma Inc.
Eisai Co., Ltd.
Bone Medical Limited
Momenta Pharmaceuticals, Inc.
Can-Fite BioPharma Ltd.
Lexicon Pharmaceuticals, Inc.
CSL Limited
WhanIn Pharmaceutical Co., Ltd.
Oscotec Inc.
Viron Therapeutics, Inc.
PLx Pharma Inc.
Endocyte, Inc.
Cardax Pharmaceuticals, Inc.
Taiwan Liposome Company, Ltd.
NasVax Ltd.
CalciMedica, Inc.
Zyngenia, Inc.
SelectX Pharmaceuticals, Inc.
DoNatur GmbH
CellAct Pharma GmbH
Arcarios BV
Inbiopro Solutions Pvt. Ltd.
Sagene Pharmaceuticals, Inc.
vida therapeutics inc.
Dong-A Socio Group
Arthritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
vancomycin hydrochloride - Drug Profile
PL-1100 - Drug Profile
MCS-18 - Drug Profile
GLPG-0555 - Drug Profile
LY-3114062 - Drug Profile
CSL-324 - Drug Profile
VT-346 - Drug Profile
CF-602 - Drug Profile
CDX-085 - Drug Profile
PL-5100 - Drug Profile
EC-1496 - Drug Profile
AMAP-102 - Drug Profile
ABC-294640 - Drug Profile
Anti-CD3 Oral Immunotherapy - Drug Profile
IBPB-001PH - Drug Profile
selegiline + NSAIDs - Drug Profile
AS-1940477 - Drug Profile
dexamethasone acetate - Drug Profile
MDC-917 - Drug Profile
Small Molecules to Inhibit MMP - Drug Profile
CAP-2.1 - Drug Profile
CAP-2.2 - Drug Profile
CAP1.1 - Drug Profile
Recombinant Protein to Inhibit TNF-Alpha for Inflammatory Diseases - Drug Profile
Small Molecules to Inhibit C-Rel for Central Nervous System, Musculoskeletal, Respiratory and Metabolic Disorders - Drug Profile
OXT-328 - Drug Profile
Peptide to Inhibit Intracellular IL-1 Receptor for Musculoskeletal, Dermatology and Central Nervous System Disorders - Drug Profile
Peptides to Inhibit MHC Class I and II for CNS Disorders and Musculoskeletal - Drug Profile
Antibody for Autoimmune Disorders and Inflammation - Drug Profile
DCB-3503 - Drug Profile
AT-132 - Drug Profile
TASP-0415914 - Drug Profile
fluticasone propionate - Drug Profile
Monoclonal Antibody to Inhibit Ang-2 and TNF-a - Drug Profile
CIIF-4 - Drug Profile
OA-1 - Drug Profile
TLC-599 - Drug Profile
Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity - Drug Profile
Small Molecule to Activate S100A8 for Arthritis - Drug Profile
CM-3457 - Drug Profile
Drugs to Activate P58IPK for Arthritis - Drug Profile
IMSB-001 - Drug Profile
RNAi Oligonucleotide for Arthritis and Gastrointestinal Disorders - Drug Profile
BN-005 - Drug Profile
BN-008 - Drug Profile
Small Molecule to Inhibit SYK for Arthritis - Drug Profile
Small Molecule to Inhibit ADAMTS-5 for Arthritis - Drug Profile
WIP-901C - Drug Profile
Small Molecules to Inhibit Cyclophilins - Drug Profile
Drug for Chronic Inflammatory Diseases - Drug Profile
Peptides to Inhibit Fibrinogen and ICAM-1 for Oncology, Inflammtion, Arthritis, Cardiovascular Disease and Bleeding Disorders - Drug Profile
Peptides to Inhibit TNF-a for Immunology, Oncology and Musculoskeletal Disorders - Drug Profile
Small Molecules to Inhibit CD147 for Immunology, Oncology, Womens Health and Musculoskeletal Disorders - Drug Profile
Small Molecules to Modulate BMP-2 for Arthritis - Drug Profile
FIV-based siRNA - Drug Profile
Gene Therapy for Arthritis - Drug Profile
NMI-4100 - Drug Profile
Arthritis - Recent Pipeline Updates
Arthritis - Dormant Projects
Arthritis - Discontinued Products
Arthritis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Arthritis, H2 2014
Number of Products under Development for Arthritis - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Development by Companies, H2 2014 (Contd..1)
Number of Products under Development by Companies, H2 2014 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Development by Companies, H2 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2014
Arthritis - Pipeline by Eli Lilly and Company, H2 2014
Arthritis - Pipeline by GlaxoSmithKline plc, H2 2014
Arthritis - Pipeline by Nemucore Medical Innovations, Inc., H2 2014
Arthritis - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014
Arthritis - Pipeline by Sylentis S.A., H2 2014
Arthritis - Pipeline by Astellas Pharma Inc., H2 2014
Arthritis - Pipeline by Eisai Co., Ltd., H2 2014
Arthritis - Pipeline by Bone Medical Limited, H2 2014
Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2014
Arthritis - Pipeline by Can-Fite BioPharma Ltd., H2 2014
Arthritis - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2014
Arthritis - Pipeline by CSL Limited, H2 2014
Arthritis - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2014
Arthritis - Pipeline by Oscotec Inc., H2 2014
Arthritis - Pipeline by Viron Therapeutics, Inc., H2 2014
Arthritis - Pipeline by PLx Pharma Inc., H2 2014
Arthritis - Pipeline by Endocyte, Inc., H2 2014
Arthritis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014
Arthritis - Pipeline by Taiwan Liposome Company, Ltd., H2 2014
Arthritis - Pipeline by NasVax Ltd., H2 2014
Arthritis - Pipeline by CalciMedica, Inc., H2 2014
Arthritis - Pipeline by Zyngenia, Inc., H2 2014
Arthritis - Pipeline by SelectX Pharmaceuticals, Inc., H2 2014
Arthritis - Pipeline by DoNatur GmbH, H2 2014
Arthritis - Pipeline by CellAct Pharma GmbH, H2 2014
Arthritis - Pipeline by Arcarios BV, H2 2014
Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014
Arthritis - Pipeline by Sagene Pharmaceuticals, Inc., H2 2014
Arthritis - Pipeline by vida therapeutics inc., H2 2014
Arthritis - Pipeline by Dong-A Socio Group, H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Arthritis Therapeutics - Recent Pipeline Updates, H2 2014
Arthritis - Dormant Projects, H2 2014
Arthritis - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Arthritis, H2 2014
Number of Products under Development for Arthritis - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Top 10 Molecule Type, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014

COMPANIES MENTIONED

Eli Lilly and Company
GlaxoSmithKline plc
Nemucore Medical Innovations, Inc.
Taisho Pharmaceutical Co., Ltd.
Sylentis S.A.
Astellas Pharma Inc.
Eisai Co., Ltd.
Bone Medical Limited
Momenta Pharmaceuticals, Inc.
Can-Fite BioPharma Ltd.
Lexicon Pharmaceuticals, Inc.
CSL Limited
WhanIn Pharmaceutical Co., Ltd.
Oscotec Inc.
Viron Therapeutics, Inc.
PLx Pharma Inc.
Endocyte, Inc.
Cardax Pharmaceuticals, Inc.
Taiwan Liposome Company, Ltd.
NasVax Ltd.
CalciMedica, Inc.
Zyngenia, Inc.
SelectX Pharmaceuticals, Inc.
DoNatur GmbH
CellAct Pharma GmbH
Arcarios BV
Inbiopro Solutions Pvt. Ltd.
Sagene Pharmaceuticals, Inc.
vida therapeutics inc.
Dong-A Socio Group
Skip to top


Psoriatic Arthritis - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 231 pages

Ask Your Question

Arthritis - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: